Новые возможности фармакотерапии хронической обструктивной болезни легких


Информация только для специалистов в сфере медицины, фармации и здравоохранения!

Новые возможности фармакотерапии хронической обструктивной болезни легких

 568

Новые возможности фармакотерапии хронической обструктивной болезни легких

Журнал "Медицинский совет. Пульмонология" № 15, 2018


А.И. Синопальников, А.Г. Романовских, Ю.Г. Белоцерковская, ФГБОУ ДПО «Российская медицинская академия непрерывного профессионального образования» Минздрава России, Москва

Ведущей терапевтической стратегией при лечении хронической обструктивной болезни легких (ХОБЛ) до настоящего времени остается применение бронходилататоров (БД), при этом наиболее перспективным представляется назначение фиксированных комбинаций длительно действующих бронхорасширяющих препаратов. Вместе с тем активно обсуждаются и вопросы противовоспалительной терапии ХОБЛ, в первую очередь целесообразность широкого использования фиксированных комбинаций ингаляционных глюкокортикостероидов (ИГКС) с длительно действующими β2-агонистами (ДДБА). Последние годы характеризуются появлением на фармацевтическом рынке значительного числа новых БД, противовоспалительных препаратов и их комбинаций. Роль и место новых препаратов в лечении ХОБЛ стабильного течения рассматриваются в представленной статье.

A.I. Sinopalnikov, A.G. Romanovskikh, Yu.G. Belotserkovskaya, Russian Medical Academy of Continuing Postgraduate Education of the Ministry of Health of Russia, Moscow

New possibilities of pharmacotherapy for chronic obstructive pulmonary disease 

The use of bronchodilators (DB) remains up to the present day the leading therapeutic strategy for the treatment of chronic obstructive pulmonary disease (COPD), in which case administration of fixed-dose combinations of long-acting bronchodilators seem the most promising. At the same time, the issues of anti-inflammatory therapy of COPD are also actively discussed, first of which is feasibility for the wide use of fixed-dose combinations of inhaled glucocorticosteroids (IHGC) with long-acting β2-agonists (LABA). Recent years are characterized by the launch of a significant number of new BDs, anti-inflammatory drugs and their combinations to the pharmaceutical market. The article considers the role and place of new drugs in the treatment of COPD having a stable course.

Новые возможности фармакотерапии хронической обструктивной болезни легких

 Загрузить файл


Список литературы

1. Diaz-Guzman E, Mannino DM. Epidemiology and prevalence of chronicobstructive pulmonary disease. Clin Chest Med, 2014, 35(1): 7-16.

2. Marchetti N, Criner GJ, Albert RK. Preventing acute exacerbations and hospital admissions in COPD. Chest, 2013, 143(5): 1444-1454.

3. Global Strategy for the Diagnosis, Management and Prevention of Chronic Obstructive Pulmonary Disease (Update 2018). Available from: http: www.goldcopd.org.

4. Barrecheguren M, Monteagudo M, Ferrer J, et al. Treatment patterns in COPD patients newly diagnosed in primary care. A population-based study. Respir Med, 2016, 111: 47-53.

5. Архипов В.В., Архипова Д.Е., Стукалина Е.Ю. и соавт. Частота встречаемости отдельных фенотипов хронической обструктивной болезни легких в Российской Федерации, их характеристики и подходы к лечению. Практическая пульмонология, 2016, 3: 20-25.

6. Ohar JA, Donohue JF. Mono-and combination therapy of long-acting bronchodilators and inhaled corticosteroids in advanced COPD. Semin Respir Crit Care Med, 2010, 31: 321-333.

7. Российское респираторное общество. Хроническая обструктивная болезнь легких. Клинические рекомендации (пересмотр 2018 года).

8. Calverley PM, Anderson JA, Celli B, et al. Salmeterol and fluticasone propionate and survival in chronic obstructive pulmonary disease. N Engl J Med, 2007, 356(8): 775-789.

9. Wilchesky M, Ernst P, Brophy JM, et al. Bronchodilator use and the risk of arrhythmia in COPD: part 2: reassessment in the larger Quebec cohort. Chest, 2012, 142: 305-311.

10. Korn S, Kerwin E, Atis S, et al. Indacaterol oncedaily provides superior efficacy to salmeterol twice-daily in COPD: a 12-week study. Respir Med, 2011, 105(5): 719-726.

11. Donohue JF, Fogarty C, Lötvall J, et al. Once-daily bronchodilators for chronic obstructive pulmonary disease: indacaterol versus tiotropium. Am J Respir Crit Care Med, 2010, 182(2): 155-162.

12. Ferguson GT, Feldman GJ, Hofbauer P, et al. Efficacy and safety of olodaterol once daily delivered via Respimat® in patients with GOLD 2-4 COPD: results from two replicate 48-week studies. Int J Chron Obstruct Pulmon Dis, 2014, 9(1): 629-645.

13. Procopiou PA, Barrett VJ, Bevan NJ et al. Synthesis and structure-activity relationships of long-acting beta2 adrenergic receptor agonists incorporating metabolic inactivation: an antedrug approach. J Med Chem, 2010, 53(11): 4522-4530.

14. Hanania NA, Feldman G, Zachgo W et al. The efficacy and safety of the novel long-acting β2 agonist vilanterol in patients with COPD: a randomized placebo-controlled trial. Chest, 2012, 142(1): 119-127.

15. Gross NJ, Skorodin MS. Role of the parasympathetic system in airway obstruction due to emphysema. N Engl J Med, 1984, 311: 421-425.

16. Tashkin DP, Celli B, Senn S, et al. A 4-year trial of tiotropium in chronic obstructive pulmonary disease. N Engl J Med, 2008, 359(15): 1543-1554.

17. Decramer M, Celli B, Kesten S, et al. Effect of tiotropium on outcomes in patients with moderate chronic obstructive pulmonary disease (UPLIFT): a prespecified subgroup analysis of a randomised controlled trial. Lancet, 2009, 374(9696): 1171-1178.

18. Lee TA, Wilke C, Joo M, et al. Outcomes associated with tiotropium use in patients with chronic obstructive pulmonary disease. Arch Intern Med, 2009, 169(15): 1403-1410.

19. Celli B, Decramer M, Kesten S, et al. Mortality in the 4-year trial of tiotropium (UPLIFT) in patients with chronic obstructive pulmonary disease. Am J Respir Crit Care Med, 2009, 180: 948-955.

20. Singh S, Loke YK, Furberg CD. Inhaled anticholinergics and risk of major adverse cardiovascular events in patients with chronic obstructive pulmonary disease: a systematic review and meta-analysis. JAMA, 2008, 300: 1439-1450.

21. Meurs H, Dekkers B G, Maarsingh H, et al. Muscarinic receptors on airway mesenchymal cells: novel findings for an ancient target. Pulm Pharmacol Ther, 2013, 26(1): 145-155.

22. Cazzola M, Molimard M. The scientific rationale for combining long-acting β2-agonists and muscarinic antagonists in COPD. Pulm Pharmacol Ther, 2010, 23(4): 257-267.

23. van Noord JA, Aumann J, Janssens E, et al. Combining tiotropium and salmeterol in COPD: Effects on airflow obstruction and symptoms. Respir Med, 2010, 104(7): 995-1004.

24. Jones PW, Singh D, Bateman ED, et al. Efficacy and safety of twice-daily aclidinium bromide in COPD patients: the ATTAIN study. Eur Respir J, 2012, 40(4): 830-836.

25. Trivedi R, Richard N, Mehta R, et al. Umeclidinium in patients with COPD: a randomised, placebo-controlled study. Eur Respir J, 2014, 43(1): 72-81.

26. LaForce C, Feldman G, Spangenthal S, et al. Efficacy and safety of twice daily glycopyrrolate in patients with stable, symptomatic COPD with moderate-to-severe airflow limitation: the GEM1 study. Int J Chron Obstruct Pulmon Dis, 2016, 11(1): 1233-1243.

27. Singh D, Roche N, Halpin D, et al. Current Controversies in the Pharmacological Treatment of Chronic Obstructive Pulmonary Disease. Am J Respir Crit Care Med, 2016, 194(5): 541-549.

28. Singh D, Jones PW, Bateman ED, et al. Efficacy and safety of aclidinium bromide/formoterol fumarate fixed-dose combinations compared with individual components and placebo in patients with COPD (ACLIFORMCOPD): a multicentre, randomised study. BMC Pulm Med, 2014, 14: 178.

29. D’Urzo AD, Rennard SI, Kerwin EM, et al. Efficacy and safety of fixed dose combinations of aclidinium bromide/formoterol fumarate: the 24-week, randomized, placebo-controlled AUGMENT COPD study. Respir Res, 2014, 15: 123.

30. Buhl R, Maltais F, Аbrahams R, et al. Tiotropium and olodaterol fixed-dose combination versus mono-components in COPD (GOLD 2-4). Eur Respir J, 2015, 45: 969-979.

31. Donohue JF, Niewoehner D, Brooks J, et al. Safety and tolerability of once-daily umeclidinium/vilanterol 125/25 mcg and umeclidinium 125 mcg in patients with chronic obstructive pulmonary disease: results from a 52-week, randomized, double-blind, placebo-controlled study. Respir Res., 2014, 15(1): 78

32. Celli B, Crater G, Kilbride S, et al. Once-daily umeclidinium/vilanterol 125/25 mcg in COPD: a randomized, controlled study. Chest, 2014, 145(5): 981-991.

33. Maleki-Yazdi M R, Kaelin T, Richard N, et al. Efficacy and safety of umeclidinium/vilanterol 62.5/25 mcg and tiotropium 18 mcg in chronic obstructive pulmonary disease: results of a 24-week, randomized, controlled trial. Respir Med, 2014, 108 (12): 1752-1760.

34. Decramer M, Anzueto A, Kerwin E, et al. Efficacy and safety of umeclidinium plus vilanterol versus tiotropium, vilanterol, or umeclidinium monotherapies over 24 weeks in patients with chronic obstructive pulmonary disease: results from two multicentre, blinded, randomised controlled trials. Lancet Respir Med, 2014, 2(6): 472-486.

35. Blair HA, Deeks ED. Umeclidinium/vilanterol: a review of its use as maintenance therapy in adults with chronic obstructive pulmonary disease. Drugs, 2015, 75: 61-74.

36. Calzetta L, Rogliani P, Matera M G, Cazzola M. A systematic review with meta-analysis of dual bronchodilation with LAMA/LABA for the treatment of stable chronic obstructive pulmonary disease. Chest, 2016, 149(5): 1181-1196.

37. Feldman GJ et al. Comparative efficacy of oncedaily umeclidinium/vilanterol and tiotropium/ olodaterol therapy in symptomatic chronic obstructive pulmonary disease: a randomized study. Adv Ther, 2017, 34: 2518-33.

38. Barnes PJ. Scientific rationale for inhaled combination therapy with long-acting beta2-agonists and corticosteroids. Eur Respir J, 2002, 19: 182-91.

39. Nannini LJ, Poole P, Milan SJ, http://et.al. Combined corticosteroid and long-acting beta2-agonist in one inhaler versus placebo for chronic obstructive pulmonary disease. Cochrane Database Syst Rev, 2013, 11: CD003794.

40. Nannini LJ, Lasserson TJ, Poole P. Combined corticosteroid and long-acting beta2-agonist in one inhaler versus long-acting beta2-agonist for chronic obstructive pulmonary disease. Cochrane Database Syst Rev, 2012, 9: CD006829.

41. Calverley PM, Anderson JA, Celli B et al. Salmeterol and fluticasone propionate and survival in chronic obstructive pulmonary disease. N Engl J Med, 2007, 356: 775-789.

42. Szafranski W, Cukier A, Ramirez A, et al. Efficacy and safety of budesonide/formoterol in the management of chronic obstructive pulmonary disease. Eur Respir J, 2003, 21: 74-81.

43. Calverley PM, Boonsawat W, Cseke Z, et al. Maintenance therapy with budesonide and formoterol in chronic obstructive pulmonary disease. Eur Respir J, 2003, 22: 912-919.

44. Drummond MB, Dasenbrook EC, Pitz M, et al. Inhaled corticosteroids in patients with stable chronic obstructive pulmonary disease: a systematic review and meta-analysis. JAMA, 2008, 300: 2407-2416.

45. Calverley P, Pauwels R, Vestbo J, et al. Combined salmeterol and fluticasone in the treatment of chronic obstructive pulmonary disease: a randomised controlled trial. Lancet, 2003, 361: 449-456.

46. Magnussen H, Disse B, Rodriguez-Roisin R, et al. Withdrawal of inhaled glucocorticoids and exacerbations of COPD. N Engl J Med, 2014, 371(14): 1285-1294.

47. Valotis A, Högger P. Human receptor kinetics and lung tissue retention of the enhancedaffinity glucocorticoid fluticasone furoate. Respiratory Research, 2007, 8: 54-62.

48. European Medicines Agency. Summary of product characteristics: Relvar Ellipta inhalation powder. 2013. http: www.ema.europa.eu/docs/en_GB/document_library/EPAR_-_Product_Information/human/002673/WC500157633.pdf.

49. Martinez FJ, Boscia J, Feldman G, et al. Fluticasone furoate/ vilanterol (100/25, 200/25 lg) improves lung function in COPD: a randomised trial. Respir Med, 2013, 107(4): 550-559.

50. Dransfield MT, Bourbeau J, Jones PW, et al. Once-daily inhaled fluticasone furoate and vilanterol versus vilanterol only for prevention of exacerbations of COPD: two replicate double-blind, parallel-group, randomised controlled trials. Lancet Respir Med, 2013, 1(3): 210-23.

51. McKeage K. Fluticasone Furoate/Vilanterol: A review of its use in chronic obstructive pulmonary disease. Drugs, 2014, 74: 1509-1522.

52. Finney L, Berry M, Singanayagam A, et al. Inhaled corticosteroids and pneumonia in chronic obstructive pulmonary disease. Lancet Respir Med, 2014, 2: 919-932.

53. Wedzicha JA, Calverley PMA, Seemungal TA, et al. The prevention of chronic obstructive pulmonary disease exacerbations by salmeterol/ fluticasone propionate or tiotropium bromide. Am J Respir Crit Care Med, 2008, 177: 19-26.

54. Pascoe S, Locantore N, Dransfield MT, et al. Blood eosinophil counts, exacerbations, and response to the addition of inhaled fluticasone furoate to vilanterol in patients with chronic obstructive pulmonary disease: a secondary analysis of data from two parallel randomised controlled trials. Lancet Respir Med, 2015, 3(6): 435-442.

55. Welte T, Miravitlles M, Hernandez P, et al. Efficacy and tolerability of budesonide/formoterol added to tiotropium in patients with chronic obstructive pulmonary disease. Am J Respir Crit Care Med, 2009, 180: 741-50.

56. Siler TM Kerwin E, Sousa AR, et al. Efficacy and safety of umeclidinium added to fluticasone furoate/vilanterol in chronic obstructive pulmonary disease: Results of two randomized studies. Respir Med, 2015, 109(9): 1155-1163.





Последние статьи